vimarsana.com
Home
Live Updates
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density : vimarsana.com
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density : vimarsana.com
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density
/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...
Related Keywords
United States ,
Princeton ,
Massachusetts ,
Hangzhou ,
Zhejiang ,
China ,
Beijing ,
Suzhou ,
Jiangsu ,
Boston ,
Shanghai ,
Guangzhou ,
Guangdong ,
Japan ,
Evenity Romosozumab ,
Los Angeles ,
Transcenta Holding ,
China Center ,
Global Medicine Development ,
Prnewswire Transcenta Holding Limited ,
Amgen ,
Group Headquarters ,
Translational Research Center ,
Product Development Center ,
Clinical Development Centers In Princeton ,
Holding Limited ,
Drug Evaluation ,
Executive Vice President ,
Chief Medical ,
Manufacturing Facility ,
Clinical Development Centers ,
External Partnering Center ,
Suzhou Industrial ,
Transcenta Holding Limited ,